HUE054362T2 - Foszfolipáz D4 elleni antitest - Google Patents

Foszfolipáz D4 elleni antitest

Info

Publication number
HUE054362T2
HUE054362T2 HUE18188036A HUE18188036A HUE054362T2 HU E054362 T2 HUE054362 T2 HU E054362T2 HU E18188036 A HUE18188036 A HU E18188036A HU E18188036 A HUE18188036 A HU E18188036A HU E054362 T2 HUE054362 T2 HU E054362T2
Authority
HU
Hungary
Prior art keywords
phospholipase
antibody
Prior art date
Application number
HUE18188036A
Other languages
English (en)
Hungarian (hu)
Inventor
Minkwon Cho
Tomohide Yamazaki
Mayuki Endo
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE054362(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of HUE054362T2 publication Critical patent/HUE054362T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE18188036A 2012-01-31 2013-01-31 Foszfolipáz D4 elleni antitest HUE054362T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012018266 2012-01-31

Publications (1)

Publication Number Publication Date
HUE054362T2 true HUE054362T2 (hu) 2021-09-28

Family

ID=47748721

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18188036A HUE054362T2 (hu) 2012-01-31 2013-01-31 Foszfolipáz D4 elleni antitest
HUE13705843A HUE041552T2 (hu) 2012-01-31 2013-01-31 Anti-foszfolipáz-D4 ellenanyag

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE13705843A HUE041552T2 (hu) 2012-01-31 2013-01-31 Anti-foszfolipáz-D4 ellenanyag

Country Status (15)

Country Link
US (2) US9944715B2 (enExample)
EP (2) EP3431504B1 (enExample)
JP (4) JP6118345B2 (enExample)
KR (1) KR102098413B1 (enExample)
CN (2) CN112442128B (enExample)
AU (2) AU2013215886B2 (enExample)
CA (1) CA2863009C (enExample)
DK (2) DK2809683T3 (enExample)
ES (2) ES2694165T3 (enExample)
HU (2) HUE054362T2 (enExample)
IL (1) IL233794B (enExample)
PL (2) PL2809683T3 (enExample)
PT (1) PT2809683T (enExample)
TR (1) TR201819828T4 (enExample)
WO (1) WO2013115410A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944715B2 (en) * 2012-01-31 2018-04-17 Sbi Biotech Co., Ltd. Anti-phospholipase D4 antibody
BR112016002001B1 (pt) * 2013-07-30 2023-04-25 SBI Biotech Co., Ltd Uso de anticorpo monoclonal, método in vitro para detectar células b ativadas, reagente para detectar células b ativadas, método in vitro para suprimir a atividade b das células ativadas, e anticorpo monoclonal
KR20160099083A (ko) * 2013-12-24 2016-08-19 아스테라스 세이야쿠 가부시키가이샤 신규 항인간 bdca-2 항체
US10759859B2 (en) 2016-01-14 2020-09-01 Bps Bioscience, Inc. Anti-PD-1 antibodies and uses thereof
EP3426298A4 (en) * 2016-03-10 2019-11-27 Viela Bio, Inc. ILT7-BINDING MOLECULES AND METHOD OF USE THEREOF
CN105624325B (zh) * 2016-03-31 2019-06-11 北京泱深生物信息技术有限公司 肺腺癌的诊治标记物
CN111278467B (zh) * 2017-10-14 2024-07-30 艾伯维公司 抗cd71可活化抗体药物缀合物和其使用方法
CN110042123B (zh) * 2019-01-07 2023-01-17 西北农林科技大学 一种通过诱导表达zfp57提高牛体细胞克隆效率的方法
WO2025085746A1 (en) * 2023-10-18 2025-04-24 Immunorx Pharma Inc. Humanized anti-s100a9 antibody
CN119120388A (zh) * 2024-10-22 2024-12-13 江苏亲科生物研究中心有限公司 一种pdpfl单克隆抗体及其试剂盒的制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098015B2 (en) * 1999-06-11 2006-08-29 Millennium Pharmaceuticals, Inc. 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
EP1578947A4 (en) 2002-12-02 2006-12-06 Abgenix Inc ANTIBODIES TAKEN AGAINST PHOSPHOLIPASE A2 AND USES THEREOF
PT1674111E (pt) * 2004-07-09 2010-12-15 Chugai Pharmaceutical Co Ltd Anticorpo anti-glipicano 3
US9944715B2 (en) * 2012-01-31 2018-04-17 Sbi Biotech Co., Ltd. Anti-phospholipase D4 antibody
BR112016002001B1 (pt) * 2013-07-30 2023-04-25 SBI Biotech Co., Ltd Uso de anticorpo monoclonal, método in vitro para detectar células b ativadas, reagente para detectar células b ativadas, método in vitro para suprimir a atividade b das células ativadas, e anticorpo monoclonal

Also Published As

Publication number Publication date
JP2019048874A (ja) 2019-03-28
AU2018200934A1 (en) 2018-03-01
TR201819828T4 (tr) 2019-01-21
WO2013115410A2 (en) 2013-08-08
AU2013215886B2 (en) 2017-11-09
PL2809683T3 (pl) 2019-03-29
AU2013215886A1 (en) 2014-08-14
US9944715B2 (en) 2018-04-17
CN104284903B (zh) 2020-10-09
CA2863009A1 (en) 2013-08-08
US20150044226A1 (en) 2015-02-12
IL233794A0 (en) 2014-09-30
DK3431504T3 (da) 2021-06-28
US20180258185A1 (en) 2018-09-13
KR102098413B1 (ko) 2020-04-07
JP2015508056A (ja) 2015-03-16
PL3431504T3 (pl) 2021-10-18
JP6118345B2 (ja) 2017-04-19
JP7244102B2 (ja) 2023-03-22
CN112442128B (zh) 2024-05-17
ES2694165T3 (es) 2018-12-18
EP2809683B1 (en) 2018-10-03
DK2809683T3 (en) 2018-12-10
IL233794B (en) 2021-04-29
JP6830471B2 (ja) 2021-02-17
KR20140126337A (ko) 2014-10-30
PT2809683T (pt) 2019-01-17
ES2873035T3 (es) 2021-11-03
US10336834B2 (en) 2019-07-02
HUE041552T2 (hu) 2019-05-28
AU2018200934B2 (en) 2019-09-12
EP2809683A2 (en) 2014-12-10
CN104284903A (zh) 2015-01-14
BR112014018539A2 (enExample) 2017-06-20
JP2017155045A (ja) 2017-09-07
BR112014018539A8 (pt) 2017-07-11
EP3431504A1 (en) 2019-01-23
CA2863009C (en) 2020-07-07
WO2013115410A3 (en) 2013-09-26
JP2021019630A (ja) 2021-02-18
CN112442128A (zh) 2021-03-05
EP3431504B1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
IL264558A (en) Anti–il–23p19 antibodies
ZA201407509B (en) Anti-fcrn antibodies
ZA201407897B (en) Protease-regulated antibodies
ZA201409358B (en) Anti-siglec- 15 antibodies
ZA201407316B (en) Anti-fgfr2 antibody
SG10201709290XA (en) Anti-H7cr Antibodies
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
IL233794B (en) Antibody against phospholipase d4
GB201220242D0 (en) Antibody
EP2804876A4 (en) NEW ANTIBODIES
SG11201504853VA (en) Immunoassay
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations